ICIs targeting PD-1/PD-L1 or CTLA-4 have shown remarkable efficacy and survival benefit in patients with advanced NSCLC, especially those with high PD-L1 expression or tumor mutational burden (94, 95). This evidence concerns the gene CD274 and neoplasm.